<DOC>
	<DOCNO>NCT01064752</DOCNO>
	<brief_summary>This uncontrolled , open-labelled pilot study explore whether minocycline measurable selective effect HIV infection central nervous system .</brief_summary>
	<brief_title>A Pilot Study Effect Minocycline Cerebrospinal Fluid HIV-1 Infection</brief_title>
	<detailed_description>This study found sequence related hypothesis : 1. inflammatory response related activation macrophage importantly contribute magnitude CNS HIV infection increase local production viral progeny ; 2. tetracycline , minocycline , anti-inflammatory property likely underlie study show drug inhibit HIV-1 infection macrophage microglia vitro reduce simian immunodeficiency virus ( SIV ) encephalitis macaque ; 3. reduce CNS monocyte/macrophage/microglial activation , minocycline therefore reduce CNS HIV infection ; 4 . CSF reflect parallel ( thus serve 'model ' ) brain infection inflammation setting ; 5. therefore , longitudinal CSF monitoring ass effect minocycline CNS HIV infection inflammation ; 6. brain injury underlying AIDS dementia complex ( ADC ) pathological substrate , HIV encephalitis , critically involve inflammatory process , broad sense , immunopathology , minocycline might eventually prove useful adjunct antiviral therapy accelerate recovery condition ( though importantly , pilot study include ADC patient ) . This uncontrolled , open-labelled pilot study explore whether minocycline measurable selective effect CSF HIV RNA concentration . There previous study examine effect human . We define priori 'biologically meaningful ' effect increase Δplasma-CSF HIV concentration &gt; 0.5 log10 copies/mL HIV RNA ( i.e . increase difference plasma CSF &gt; 0.5 log10 copies/mL HIV RNA compare baseline difference ) face unchanged reduce plasma HIV RNA . Reductions absolute level CSF plasma HIV well reduction CSF inflammatory marker T cell activation also interest . This study serve initial exploration possible therapeutic effect minocycline CNS HIV infection . Our overall strategy begin pilot study , result look promising ( biological effect lack toxicity ) , use result design control trial , either single multi-institutional study . Additionally , study share almost identical design another propose study examine effect atorvastatin CSF HIV infection . While neither study control , yield pilot comparative result .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Minocycline</mesh_term>
	<criteria>1 . HIV infection plasma CSF HIV RNA concentration ( use Roche Amplicor assay ) &gt; 1,000 copies/ mL ( available baseline LP ) . 2 . Off antiretroviral therapy ( ART ) &gt; 6 week study plan begin treatment study duration . ( The decision whether subject take antiretroviral therapy make subject consultation his/her primary care provider prior screen study . ) 3 . Predicted adherence medication . 4 . Capable provide informed consent . 5 . &gt; 18 year old 6 . CD4 cell count &gt; 150 cells/μL ( though likely , , &gt; 250 cells/μL ) . 7 . When available , subject screen stability blood CD4 HIV RNA level . 1 . Taking tetracycline within 6 month history adverse reaction minocycline another tetracycline . 2 . Enhanced risk lumbar puncture , include document suspected cerebral mass lesion predispose brain herniation bleed diathesis . 3 . Pregnancy expectation pregnancy study . 4 . Active opportunistic infection active neurological disease might confound evaluation . 5 . ADC Stage &gt; 1 . 6 . Hemoglobin &lt; 10 Gms/dL . 7 . BUN creatine normal limit . 8 . Taking drug know reduce metabolism minocycline thus increase probability toxicity .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>Minocycline</keyword>
	<keyword>HIV-1</keyword>
	<keyword>Immune activation</keyword>
	<keyword>Cerebrospinal fluid</keyword>
	<keyword>Observational</keyword>
</DOC>